Figure 1.
DSTYK is amplified and high levels of the gene correlate with poor prognosis in NSCLC patients. (A) Mutated kinase coding genes of a syngeneic SCC cell line (UN-SCC680) derived from a N-nitroso-tris-chloroethylurea chemically induced mouse model in A/J mice. Orange highlights tyrosine kinase genes. (B) Percentage of patients with DSTYK alteration from lung cancer. From Pan-Cancer TCGA data. (C) DSTYK CNV in normal (n = 960) and tumoral (n = 904) samples from NSCLC patients from the TCGA project. A t test was performed to compared both groups; P value = 2.2 × 10−16. (D) DSTYK CNV in paired normal and tumoral samples (n = 832) of NSCLC patients from the TCGA project. 82% of tumor samples showed DSTYK CN gain. (E) Kaplan–Meier plot. OS significantly decreases in lung cancer patients from the TCGA project with DSTYK CN gain (CNV ≥ 3; n, CVN < 3 = 951; n, CNV ≥ 3 = 40). Log-rank test P = 0.01. (F) Dot plot shows the correlation between CNV and mRNA expression of DSTYK. Patients with CNV ≥3 present significantly higher expression of DSTYK mRNA (n, CVN < 3 = 954; n, CNV ≥ 3 = 54). A t test was performed to compared both groups; P value = 8.5 × 10−7. (G) Kaplan–Meier plot. PFS significantly decreases in lung cancer patients with high DSTYK mRNA expression (Q1). (n, low = 736; n, high = 246). Log-rank test P = 2.4 × 10−8. Data are from https://kmplot.com/. (H) Kaplan–Meier plot. OS significantly decreases in lung cancer patients with high DSTYK mRNA expression (Q1). n, low = 1452; n, high = 373. Log-rank test P = 0.036. Data are from https://kmplot.com/. (I) Percentage of LUAD and LUSC patients with CN gain of DSTYK (CN > 3). Data from the TCGA project. (J) DSTYK CNV evaluation in CIMA-CUN-cohort patients by qRT-PCR. (K) FISH analysis of DSTYK (Amp) and (NoAmp) patients. Scale bar: 5 µm. A t test was performed to compare cells with DSTYK CN (P value = 0.04); median average of DSTYK CN (P = 0.02) and maximum CN of DSTYK (P = 0.038). (L) Cropped images from the Western blot analysis of DSTYK in frozen tumor samples from CIMA-CUN cohort patients with DSTYK CN gain and diploid number of DSTYK. *, P < 0.05; ***, P < 0.001. Source data are available for this figure: SourceData F1.

DSTYK is amplified and high levels of the gene correlate with poor prognosis in NSCLC patients. (A) Mutated kinase coding genes of a syngeneic SCC cell line (UN-SCC680) derived from a N-nitroso-tris-chloroethylurea chemically induced mouse model in A/J mice. Orange highlights tyrosine kinase genes. (B) Percentage of patients with DSTYK alteration from lung cancer. From Pan-Cancer TCGA data. (C) DSTYK CNV in normal (n = 960) and tumoral (n = 904) samples from NSCLC patients from the TCGA project. A t test was performed to compared both groups; P value = 2.2 × 10−16. (D) DSTYK CNV in paired normal and tumoral samples (n = 832) of NSCLC patients from the TCGA project. 82% of tumor samples showed DSTYK CN gain. (E) Kaplan–Meier plot. OS significantly decreases in lung cancer patients from the TCGA project with DSTYK CN gain (CNV ≥ 3; n, CVN < 3 = 951; n, CNV ≥ 3 = 40). Log-rank test P = 0.01. (F) Dot plot shows the correlation between CNV and mRNA expression of DSTYK. Patients with CNV ≥3 present significantly higher expression of DSTYK mRNA (n, CVN < 3 = 954; n, CNV ≥ 3 = 54). A t test was performed to compared both groups; P value = 8.5 × 10−7. (G) Kaplan–Meier plot. PFS significantly decreases in lung cancer patients with high DSTYK mRNA expression (Q1). (n, low = 736; n, high = 246). Log-rank test P = 2.4 × 10−8. Data are from https://kmplot.com/. (H) Kaplan–Meier plot. OS significantly decreases in lung cancer patients with high DSTYK mRNA expression (Q1). n, low = 1452; n, high = 373. Log-rank test P = 0.036. Data are from https://kmplot.com/. (I) Percentage of LUAD and LUSC patients with CN gain of DSTYK (CN > 3). Data from the TCGA project. (J) DSTYK CNV evaluation in CIMA-CUN-cohort patients by qRT-PCR. (K) FISH analysis of DSTYK (Amp) and (NoAmp) patients. Scale bar: 5 µm. A t test was performed to compare cells with DSTYK CN (P value = 0.04); median average of DSTYK CN (P = 0.02) and maximum CN of DSTYK (P = 0.038). (L) Cropped images from the Western blot analysis of DSTYK in frozen tumor samples from CIMA-CUN cohort patients with DSTYK CN gain and diploid number of DSTYK. *, P < 0.05; ***, P < 0.001. Source data are available for this figure: SourceData F1.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal